Welcome to our dedicated page for Medicus Pharma SEC filings (Ticker: MDCX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Medicus Pharma Ltd. (NASDAQ: MDCX) SEC filings page on Stock Titan provides direct access to the company’s U.S. regulatory disclosures, including registration statements, current reports and financing-related documents. Medicus is an Ontario-incorporated biotech and life sciences company focused on SkinJect™, a doxorubicin microneedle array for basal cell carcinoma, and Teverelix, a long-acting GnRH antagonist for prostate and urologic indications.
Key filing types for MDCX include registration statements on Form S-1, which describe offerings and resale registrations tied to standby equity purchase agreements, warrant exercises and acquisition-related consideration shares. These S-1 filings outline the company’s business, risk factors, pipeline programs and capital structure in detail. Investors can review sections covering the SkinJect™ and Teverelix clinical programs, as well as the terms of equity facilities with counterparties such as YA II PN, Ltd. (Yorkville) and Armistice Capital Master Fund Ltd.
Current reports on Form 8-K document material events such as the acquisition of Antev Limited, warrant inducement agreements, new debenture financings, non-binding memoranda of understanding, and updates on clinical and regulatory milestones. For example, 8-K filings describe the Antev transaction that added Teverelix to the pipeline, the terms of a debenture issued to Yorkville, and inducement arrangements for the exercise of outstanding warrants.
Through this page, users can also monitor unregistered sales of equity securities disclosed under Item 3.02 of Form 8-K, which provide insight into how Medicus funds its clinical development activities. While insider Form 4 reports are not summarized in the provided data, Stock Titan’s platform is designed to surface such ownership changes when available.
How Stock Titan helps
Stock Titan enhances these filings with AI-powered summaries that explain complex documents in plain language, highlight key terms in S-1 and 8-K filings, and point out items relevant to Medicus’s SkinJect™ and Teverelix programs. Real-time EDGAR updates mean new MDCX filings appear quickly, and investors can use this page to track registration statements, financing terms and other regulatory disclosures without reading every page of each filing.
Medicus Pharma Ltd. has filed a prospectus supplement relating to 1,115,500 common shares issuable upon the exercise of previously registered warrants and uses it to update investors on new financing activity. The company entered into a warrant inducement agreement with an institutional holder to amend existing warrants to buy up to 2,680,000 common shares at $1.92 per share, in exchange for the holder receiving 4,020,000 new unregistered warrants with a $2.00 exercise price, expiring June 5, 2031. One series of these new warrants allows the company, under certain conditions, to force exercise if the average share VWAP reaches $10.00 over ten trading days, and the company expects approximately $5.1 million in gross proceeds from the existing warrant exercises before a 6% fee to its advisor.
The filing also details recent sales of 680,893 common shares to Yorkville under a standby equity purchase agreement, generating about $1,500,905 in aggregate consideration, with part of the net proceeds used to prepay a portion of a debenture owed to Yorkville. Medicus plans to register the resale of the shares underlying the new warrants in a future registration statement and notes that the new warrants and related shares are currently unregistered, issued under a private offering exemption.
Medicus Pharma Ltd. entered a warrant inducement agreement with an accredited institutional holder to encourage exercise of existing warrants to buy up to 2,680,000 common shares at an amended exercise price of $1.92 per share. In return, the holder will receive new unregistered warrants for up to 4,020,000 additional shares at $2.00 per share, split into two series expiring on June 5, 2031, with one series allowing the company to require exercise if the 10-day average VWAP reaches $10.00.
The company expects approximately $5.1 million in gross proceeds from the exercise of the existing warrants, before fees including a 6.0% cash fee to Maxim Group LLC. Medicus also reported prior sales of 680,893 common shares to Yorkville under a standby equity purchase agreement for approximately $1,500,905 in aggregate, using part of the net proceeds to prepay a portion of an outstanding debenture. The company plans to file a registration statement to permit resale of the new warrant shares.
Medicus Pharma Ltd. updates its prospectus for an offering of up to 2,680,000 common shares and attaches a recent current report. The supplement incorporates a Form 8-K that details executive leadership changes while keeping the original S-1 prospectus in effect.
The company’s common shares trade on Nasdaq under the symbol MDCX, with a last reported price of $1.73 on December 3, 2025. The filing confirms Medicus Pharma’s status as an emerging growth company and reminds investors of the high risks described in the underlying prospectus.
The Form 8-K reports that Chief Financial Officer James Quinlan resigned as an officer and employee effective November 28, 2025, after being on medical leave since September 12, 2025. Effective December 1, 2025, President Carolyn Bonner, who had been acting CFO, was appointed Chief Financial Officer and will continue serving as President under a five-year employment agreement with a $395,000 base salary and escalating target bonus opportunities.
Medicus Pharma Ltd. is registering up to 2,680,000 common shares for resale by Armistice Capital Master Fund Ltd. These shares are issuable upon exercise of 2,680,000 Private Warrants with a $3.75 exercise price and a July 15, 2030 expiry. Medicus is not selling shares itself and will not receive proceeds from any resale, though it may receive up to $10,050,000 if the Private Warrants are exercised.
The company is a clinical-stage life sciences business developing SkinJect™, a dissolvable microneedle patch for basal cell carcinoma, and Teverelix for high‑risk prostate cancer and acute urinary retention. It recently acquired 98.6% of Antev Limited to advance Teverelix and has begun Phase 2 SkinJect™ trials and regulatory initiatives in the U.S. and U.K.
Medicus remains deeply loss‑making, with a net loss of $27.3 million for the nine months ended September 30, 2025 and an accumulated deficit of about $56.2 million, resulting in a shareholders’ deficit and an auditor‑flagged substantial doubt about its ability to continue as a going concern. The company expects to need significant additional financing, faces extensive regulatory and clinical risk, and relies heavily on key licenses and successful integration of Antev. Its shares trade on Nasdaq under “MDCX”.
Medicus Pharma Ltd. has filed a prospectus supplement covering up to 3,710,000 common shares under an existing S-1 registration and attached its latest quarterly report. For the nine months ended September 30, 2025, the company reported a net loss of $27,259,804, driven by operating expenses of $26,568,702, including an $8,717,475 in-process R&D charge for the Antev Teverelix acquisition. Cash and cash equivalents were $8,662,091, with total assets of $9,977,661 and a shareholders’ deficit of $804,890. A going concern warning highlights reliance on continued financings, including an $8,000,000 debenture and a $15,000,000 standby equity purchase agreement, while common shares outstanding reached 22,029,144 as of November 11, 2025.
Medicus Pharma Ltd. has filed a prospectus supplement registering up to 1,397,184 common shares and incorporating its latest quarterly report. The company is a clinical-stage biotech developing dissolvable microneedle patches for skin cancers and, through newly acquired Antev, a GnRH antagonist (Teverelix) for prostate-related indications.
As of September 30, 2025, Medicus held $8.7 million in cash and total assets of about $10.0 million, but current liabilities of $10.7 million left shareholders with a deficit of roughly $0.8 million. There were 22,029,144 common shares outstanding as of November 11, 2025, and the Nasdaq share price was $2.26 on November 13, 2025.
The company reported a net loss of $15.98 million for the quarter and $27.26 million for the nine months ended September 30, 2025, driven by higher general and administrative and R&D spending and an $8.72 million in-process R&D charge related to Teverelix. Operations have been funded by equity offerings, warrant exercises, a standby equity purchase agreement and new debentures, and management discloses substantial doubt about the ability to continue as a going concern without additional capital.
Medicus Pharma Ltd. is registering 2,260,000 common shares issuable upon the exercise of warrants under its Form S-1, via a new prospectus supplement that incorporates its Quarterly Report on Form 10-Q for the period ended September 30, 2025. The company reported a net loss attributable to common shareholders of $20,935,830 for the quarter and $32,214,322 for the nine months, driven by higher general and administrative costs, increased research and development spending, and an $8,717,475 charge for in-process R&D from the Antev acquisition. Cash and cash equivalents were $8,662,091 with debentures of $6,785,812 and a shareholders’ deficit of $804,890. The company discloses substantial doubt about its ability to continue as a going concern and highlights reliance on warrant exercises, a standby equity purchase agreement and other financings. As of November 11, 2025, it had 22,029,144 common shares outstanding.
Medicus Pharma Ltd. is registering 1,115,500 common shares issuable upon exercise of existing public warrants. The warrants have a $4.64 exercise price and expire on November 15, 2029, while the common shares and warrants trade on Nasdaq under "MDCX" and "MDCXW." As of November 11, 2025, the company had 22,029,144 common shares outstanding.
For the nine months ended September 30, 2025, Medicus reported a net loss of $27.3 million, driven by $26.6 million in operating expenses, including $12.7 million in general and administrative costs, $5.1 million in R&D, and an $8.7 million in-process R&D charge from the Antev acquisition. Shareholders’ equity shifted to a deficit of about $0.8 million despite multiple equity raises and warrant exercises.
Cash and cash equivalents were $8.7 million against a working capital deficit and debentures of $6.8 million. Management discloses substantial doubt about the company’s ability to continue as a going concern and highlights reliance on additional financings, including a standby equity purchase agreement of up to $15 million, warrant exercises, and other capital sources to fund ongoing clinical programs.
Medicus Pharma Ltd. has filed a prospectus supplement covering up to 7,500,000 common shares under its Form S-1, updating the offering with new quarterly information. The attached Form 10-Q shows a clinical-stage biotech expanding its pipeline but generating substantial losses as it funds development and acquisitions.
For the nine months ended September 30, 2025, the company recorded a net loss of $27,259,804, driven by $26,568,702 in operating expenses that include $8,717,475 of in-process R&D expense from the Antev acquisition, higher general and administrative costs, and increased research and development spending. Cash and cash equivalents were $8,662,091 as of September 30, 2025.
Medicus raised capital through a Regulation A unit offering, a June 2025 public offering, warrant exercises, a standby equity purchase agreement and new debentures, but still reported a shareholders’ deficit and a working capital deficit. The company discloses substantial doubt about its ability to continue as a going concern without additional financing. As of November 11, 2025, it had 22,029,144 common shares issued and outstanding.